Metris Therapeutics Ltd.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Metris Therapeutics Ltd.
The dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Windhover's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Cancer Diagnostics, features profiles of Amepersand Medical Corp., Amplistar Inc., Cell Works Inc and Cogs LLC. Plus these selected Start-ups across Health Care: Metris Therapeutics Ltd., Cardeon Corp., LabDat Inc. and Sutura Inc.
Existing drug therapies for endometriosis, including drugs that block estrogen and GnRH agonists bear troubling side effects. Metris Therapeutics hopes to avoid these by taking a different path to the disease. The company's founders were among the first to identfiy increased levels of vascular endothelial growth factor (VEGF) in the peritoneal fluid of women with endometriosis. Metris has therfore set out to develop a product to block VEGF's action.